---
title: "Moderna advances in vivo CAR-T candidate mRNA-6007 into early development for autoimmune diseases"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290822266.md"
description: "Moderna advanced its in vivo CAR-T candidate mRNA-6007 into early development for autoimmune diseases, initially targeting systemic lupus erythematosus. During its Science Day event, the company also highlighted ongoing Phase 1/2 studies for mRNA-2808 in multiple myeloma and moved mRNA-2151 toward early development in ovarian cancer. Additionally, Moderna expects further data readouts later in 2026, including Phase 1 part B results for mRNA-1195 in EBV-associated conditions."
datetime: "2026-06-25T11:20:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290822266.md)
  - [en](https://longbridge.com/en/news/290822266.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290822266.md)
---

# Moderna advances in vivo CAR-T candidate mRNA-6007 into early development for autoimmune diseases

-   Moderna outlined new early-stage pipeline moves at its Science Day event, with no new trial results disclosed in the update. \* A Phase 1⁄2 study of mRNA-2808 in multiple myeloma is ongoing, with early signals described as encouraging for the T-cell engager approach. \* The company is moving mRNA-2151, a second multiplexed T-cell engager program, toward early development in ovarian cancer, supported by the mRNA-2808 signal. \* mRNA-6007, an in vivo CAR-T program for autoimmune disease, entered early development with an initial clinical focus on systemic lupus erythematosus. \* Moderna expects additional readouts later in 2026, including Phase 1 part B data for mRNA-1195 in EBV-associated conditions such as multiple sclerosis. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief on June 25, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [MRNX.US](https://longbridge.com/en/quote/MRNX.US.md)
- [MRNY.US](https://longbridge.com/en/quote/MRNY.US.md)

## Related News & Research

- [This Stock Has Already Doubled This Year and Is Still Racing Towards a Major Catalyst](https://longbridge.com/en/news/290916339.md)
- [Moderna spotlights expanding mRNA pipeline at Science Day event](https://longbridge.com/en/news/290819631.md)
- [Moderna Maintained at Hold as Analyst Weighs Leading mRNA Platform Against Early-Stage Pipeline Risks](https://longbridge.com/en/news/290970667.md)
- [Moderna publishes Science Day 2026 presentation](https://longbridge.com/en/news/290839905.md)
- [Moderna’s mRNA flu vaccine passes FDA AdCom, review underway](https://longbridge.com/en/news/290435765.md)